**Background of HBP1 Antibody**
The HBP1 (HMG-box transcription factor 1) antibody is a tool used to detect and study the HBP1 protein, a member of the high-mobility group (HMG)-box family of transcriptional regulators. HBP1 functions as a tumor suppressor and cell cycle regulator by binding to specific DNA sequences to repress or activate target genes involved in proliferation, differentiation, and senescence. It is notably implicated in regulating pathways like Wnt/β-catenin and Rb-E2F, often by suppressing oncogenic signals or inducing cell cycle arrest through proteins such as p21 and p16INK4a.
HBP1 antibodies are widely utilized in research applications, including Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), to analyze HBP1 expression levels, subcellular localization, and interactions in various tissues or cell lines. Studies have linked HBP1 dysregulation to cancers (e.g., breast, liver, and colorectal), neurodegenerative diseases, and aging, highlighting its role in maintaining genomic stability and cellular homeostasis.
Developed against specific epitopes of human HBP1. these antibodies are validated for specificity and sensitivity, often in knockout-validated models. Researchers rely on HBP1 antibodies to explore its dual roles in tumor suppression and context-dependent oncogenic activity, providing insights into therapeutic targets for cancer and age-related disorders. Commercial HBP1 antibodies are available from multiple suppliers, tailored for diverse experimental needs.